

This is the peer reviewed version of the following article:

Early predictors of disability of paediatric-onset AQP4-IgG-seropositive neuromyelitis optica spectrum disorders / Camera, V.; Messina, S.; Elhadd, K. T.; Sanpera-Iglesias, J.; Mariano, R.; Hacohen, Y.; Dobson, R.; Meletti, S.; Wassmer, E.; Lim, M. J.; Huda, S.; Hemingway, C.; Leite, M. I.; Ramdas, S.; Palace, J.. - In: JOURNAL OF NEUROLOGY, NEUROSURGERY AND PSYCHIATRY. - ISSN 1468-330X. - 93:1(2022), pp. 101-111. [10.1136/jnnp-2021-327206]

*Terms of use:*

The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

26/04/2024 05:04

(Article begins on next page)

Journal of  
**Neurology, Neurosurgery  
 & Psychiatry**

**Early predictors of disability of paediatric-onset AQP4-IgG seropositive neuromyelitis optica spectrum disorders**

Journal:	<i>Journal of Neurology, Neurosurgery, and Psychiatry</i>
Manuscript ID	jnnp-2021-327206.R1
Article Type:	Original research
Date Submitted by the Author:	19-Aug-2021
Complete List of Authors:	<p>Camera, Valentina; University of Oxford, Nuffield Department of Clinical Neuroscience; University of Modena and Reggio Emilia, Department of Biomedical, Metabolic and Neurosciences          Messina, Silvia; Oxford University Hospitals NHS Trust, Department of Clinical Neurosciences, John Radcliffe Hospital; University of Oxford, Nuffield Department of Clinical Neuroscience          Elhadd, Kariem Tarek; The Walton Centre NHS Foundation Trust, The Walton Centre for Neurology and Neurosurgery          Sanpera-Iglesias, Julia; Evelina London Children's Hospital, Children's Neurosciences,          Mariano, Romina; Oxford University Hospitals NHS Trust, Department of Clinical Neurosciences, John Radcliffe Hospital; University of Oxford, Nuffield Department of Clinical Neuroscience          Hacohen, Yael; Great Ormond Street Hospital For Children NHS Foundation Trust, Neurology Department; University College London, Department of Neuroinflammation, Queen Square MS Centre          Dobson, Ruth; Queen Mary University of London, Preventive Neurology Unit, Wolfson Institute of Preventive Medicine          Meletti, Stefano; University of Modena and Reggio Emilia, Department of Biomedical, Metabolic and Neurosciences; Azienda Ospedaliero-Universitaria di Modena, Neurology Unit          Wassmer, Evangeline; Birmingham Women's and Children's Hospitals NHS Foundation Trust, Neurology          Lim, Ming; Evelina London Children's Hospital, Children's Neurosciences; King's College London, Department of Women and Children's Health          Huda, Saif; The Walton Centre NHS Foundation Trust, The Walton Centre for Neurology and Neurosurgery          Hemingway, Cheryl; Great Ormond Street Hospital for Children, Department of Paediatric Neurology          Leite, Maria Isabel; University of Oxford, Nuffield Department of Clinical Neurosciences; Oxford University Hospitals NHS Trust, Department of Clinical Neuroscience, John Radcliffe Hospital          Ramdas, Sithara; Oxford Radcliffe Hospitals NHS Trust, Department of Paediatric Neurology; University of Oxford, Department of Paediatrics          Palace, Jacqueline; University of Oxford, Nuffield Department of Clinical Neurosciences; Oxford University Hospitals NHS Trust, Department of Clinical Neuroscience, John Radcliffe Hospital</p>
<b>Specialty</b>:	Demyelinating diseases

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Keywords:	PAEDIATRIC NEUROLOGY

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

# Early predictors of disability of paediatric-onset AQP4-IgG seropositive neuromyelitis optica spectrum disorders

Valentina Camera, MD<sup>1,2</sup>; Silvia Messina, MD<sup>1</sup>; Kariem T. Elhadd, MD<sup>3</sup>; Julia Sanpera-Iglesias, MD<sup>4</sup>; Romina Mariano, MD<sup>1</sup>; Yael Hacoheh, MD, PhD<sup>5,6</sup>; Ruth Dobson, MD, PhD<sup>7</sup>; Stefano Meletti, MD, PhD<sup>2</sup>; Evangeline Wassmer, MD<sup>8</sup>; Ming Lim, MD, PhD<sup>4,9</sup>; Saif Huda, MD, DPhil<sup>3</sup>; Cheryl Hemingway, MD, PhD<sup>5</sup>; Maria Isabel Leite, MD, DPhil<sup>1</sup>; Sithara Ramdas, MD<sup>10</sup>; Jacqueline Palace, MD<sup>1</sup>

## Affiliations

<sup>1</sup> Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom – Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford University Hospitals NHS Trust, Oxford, United Kingdom

<sup>2</sup> Department of Biomedical, Metabolic and Neurosciences, University of Modena and Reggio Emilia, Modena, Italy - Neurology Unit, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy

<sup>3</sup> The Walton Centre for Neurology and Neurosurgery, Walton Centre NHS Foundation Trust, Liverpool, United Kingdom

<sup>4</sup> Children's Neurosciences, Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom

<sup>5</sup> Department of Paediatric Neurology, Great Ormond Street Hospital for Children, London, United Kingdom

<sup>6</sup> Department of Neuroinflammation, Queen Square Multiple Sclerosis Centre, Institute of Neurology, University College London, London, United Kingdom

<sup>7</sup> Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, United Kingdom - The Royal London Hospital, London, United Kingdom

<sup>8</sup> Department of Paediatric Neurology, Birmingham Children's Hospital, Birmingham, United Kingdom

<sup>9</sup> Department of Women and Children's Health, Faculty of Life Sciences and Medicine, King's College London, London, United Kingdom

<sup>10</sup> Department of Paediatrics, University of Oxford, Oxford, United Kingdom – Department of Paediatric Neurology, John Radcliffe Hospital, Oxford University Hospitals NHS Trust, Oxford, United Kingdom

**Corresponding author:** Prof. Jacqueline Palace  
Nuffield Department of Clinical Neurosciences,  
West Wing, John Radcliffe Hospital,  
University of Oxford,  
Oxford OX3 9DU  
United Kingdom  
Telephone number: 01865231869  
E-mail: jacqueline.palace@ndcn.ox.ac.uk

1  
2  
3 Number of references: 25  
4 Abstract words count: 258  
5 Manuscript body words count: 3990  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Confidential: For Review Only

## Abstract

### Objective:

To describe onset clinical features predicting time to first relapse and time to long-term visual, motor, and cognitive disabilities in paediatric-onset aquaporin-4-antibody (AQP4-IgG) neuromyelitis optica spectrum disorders (NMOSD).

### Methods:

In this retrospective UK multicenter cohort study, we recorded clinical data of paediatric-onset AQP4-IgG NMOSD. Univariate and exploratory multivariable Cox proportional hazard models were used to identify long-term predictors of permanent visual disability, EDSS 4 and cognitive impairment.

### Results:

We included 49 paediatric-onset AQP4-IgG patients (38.8% White, 34.7% Black, 20.4% Asians and 6.1% Mixed), mean onset age of  $12 \pm 4.1$  years, and 87.7% were females. Multifocal onset presentation occurred in 26.5% of patients and optic nerve (47%), area postrema/brainstem (48.9%) and encephalon (28.6%) were the most involved areas. Overall, 52.3% of children had their first relapse within one year from disease onset. Children with onset age  $< 12$  years were more likely to have an earlier first relapse ( $p=0.030$ ), despite showed no difference in time to immunosuppression compared to those aged 12-18 years at onset. At the cohort median disease duration of 79 months, 34.3% had developed permanent visual disability, 20.7% EDSS 4 and 25.8% cognitive impairment. Visual disability was associated with White race ( $p=0.032$ ) and optic neuritis presentations ( $p=0.002$ ). Cognitive impairment was predicted by cerebral syndrome presentations ( $p=0.048$ ), particularly if resistant to steroids ( $p=0.034$ ).

### Conclusions:

Age at onset, race, onset symptoms and resistance to acute therapy at onset attack predict first relapse and long-term disabilities. The recognition of these predictors may help to power future paediatric clinical trials and to direct early therapeutic decisions in AQP4-NMOSD.

## INTRODUCTION

Neuromyelitis optica spectrum disorder (NMOSD) is an inflammatory demyelinating disease of the central nervous system (CNS) affecting predominantly the optic nerves and spinal cord<sup>1</sup>. Approximately 60-80% have disease-specific aquaporin-4 antibodies (AQP4-IgG) in the serum which, due to the astrocytic location of the AQP4 water channels, lead to a primary autoimmune astrocytopathy<sup>2,3,4</sup> with a characteristic relapsing course. Only about 5% of AQP4-IgG positive NMOSD have a paediatric-onset<sup>4,5</sup>. Data on long-term clinical outcomes of AQP4-IgG positive paediatric patients are sparse due to the rarity of the disease<sup>6,7,8,9</sup> and further evidence is needed particularly because of the new therapies coming through<sup>5</sup>. This is a long-term outcome study of a relatively large single country paediatric-onset AQP4-IgG NMOSD cohort recruited from several UK neurology centers.”

## METHODS

We retrospectively analysed data prospectively collected from databases and clinical notes (recorded from 1980 to July 2020) of patients with paediatric-onset (defined as <18 years) AQP4-IgG seropositive NMOSD (diagnosed according to the 2015 diagnostic criteria<sup>1</sup>) from six tertiary UK NMO centres: (i) John Radcliffe Hospital, Oxford, UK (adult and paediatric); (ii) Great Ormond Street Hospital, London, UK (paediatric); (iii) Walton Centre, Liverpool, UK (adult and paediatric); (iv) Evelina London Children’s Hospital, UK (paediatric); (v) Birmingham Children's Hospital, Birmingham, UK (paediatric); and (vi) Royal London Hospital, London, UK (adult). The presence of AQP4-IgGs was identified in the Autoimmune Neurology Laboratory using a cell-based assay as described by Waters et al<sup>10</sup>.



1  
2  
3 All data was collected as standard clinical care at the respective centres (6 monthly  
4 neurological and ophthalmological follow-up in remission, serum AQP4-IgG testing,  
5  
6 diagnostic MRIs and CSFs where diagnostically useful) and subsequently shared  
7  
8 according to local trust policy with the coordinating centre in Oxford (Oxford  
9  
10 Research Ethics Committee C Ref:10/H0606/56). Information was collected on sex,  
11  
12 age at onset, race, onset attack type and severity at nadir, relapses, acute and  
13  
14 maintenance immunosuppressive therapy, time to first relapse, time to long-term  
15  
16 visual disability (best eye worse than 6/36 for longer than six months), motor  
17  
18 disability (walk  $\leq$  500 m unaided for longer than six months-Expanded Disability  
19  
20 Status Scale 4 [EDSS 4]), and cognitive impairment (defined by neuropsychological  
21  
22 assessments or documented learning disability requiring extra support at school).  
23  
24 Neurocognitive testing was performed using a varied battery of age appropriate  
25  
26 standard tests (Supplementary Table 1) of cognition dictated by clinical need as  
27  
28 outlined<sup>11</sup> by clinical psychologist/neuropsychologist working with tertiary adult  
29  
30 and/or paediatric neuroscience centres. These tests typically include a measure of  
31  
32 episodic memory, language, attention, and executive functioning. Cognition was  
33  
34 considered impaired if any test within these domains fell below the 5th percentile. In  
35  
36 patients where formal cognitive assessment was not performed, cognitive impairment  
37  
38 was pragmatically defined as documented learning disability requiring extra support  
39  
40 at school was defined as requiring a minimum of a special educational needs  
41  
42 coordinator. Table 1 details the variables collected for each patient and definitions of  
43  
44 the clinical phenotypes, severity scoring and visual, motor and cognitive disability  
45  
46 outcomes.  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1: List of the collected clinical variables and definitions**

- Sex: Male and Female
- Age at onset (continuous variable), Age at onset subgroups :< 12 years and 12-18 years
- Race: White, Asian, Black and Mixed
- Disease duration (months)
- Onset syndromes:
  - ◊ monolateral or bilateral optic neuritis (ON);
  - ◊ transverse myelitis (TM);
  - ◊ area postrema syndrome and/or brainstem syndrome (BS);
  - ◊ cerebral syndrome (acute disseminated encephalomyelitis syndrome [ADEM], diencephalic syndromes, or encephalopathies without typical MRI features of ADEM) (CS);
  - ◊ multifocal syndromes
- Severity of the onset attack, defined as:
  - ◊ inability to walk unaided at TM attacks nadir;
  - ◊ visual acuity 6/60 or worse in affected eye at ON attacks nadir;
  - ◊ documented reduction of consciousness or vomiting for more than 7 days with weight loss at CS and BS attacks nadir
- Age (years) and time (months) from onset to aquaporin-4 antibodies (AQP4-IgG) detection
- Acute therapy of the onset attack: intravenous methylprednisolone (IVMP), intravenous immunoglobulins (IVIG), plasma exchange (PLEX), no therapy
- Relapsing or monophasic course
- Time to first relapse (months)
- Annualized relapse rate (ARR) before and after the immunosuppressive therapy initiation
- Time from onset to immunosuppressive therapy initiation (months)
- First and current long-term immunosuppressive therapy: azathioprine (AZA), mycophenolate mofetil (MMF) and rituximab (RTX), methotrexate, cyclophosphamide
- Discontinuation of long-term immunosuppressive therapy due to relapse or intolerance
- Development of permanent visual disability after the onset attack or during the disease course\*, defined as visual acuity in best eye worse than 6/36 on Snellen chart
- Time to permanent visual disability (months)
- Development of permanent motor disability after the onset attack or during the disease course\*, defined as a persisting Expanded Disability Status Scale (EDSS) score 4 or EDSS 6 or EDSS 8
- Time to permanent motor disability (EDSS 4) (months)
- Development of cognitive impairment after the onset attack or during the disease course\*, defined by neuropsychological assessments and/or documented learning disability requiring extra support at school
- Time to cognitive impairment (months)
- Death after the onset attack or during the disease course
- Time to death (months)

\* recorded at 6 months from onset attack or confirmed at 6 months after the last relapse

## Statistical analysis

Descriptive and groups comparison analysis were conducted considering the low number of observations. Categorical variables were presented as absolute frequencies and percentages and continuous variables as mean  $\pm$  standard deviation (SD) or median and range. Mean and median differences between two groups were analysed using unpaired t-test or Mann-Whitney U-test, respectively. ANOVA and Kruskal Wallis tests were used to compare means and medians of more than two groups. Fisher's exact test was applied to compare proportions among groups. We used Kaplan-Meier curves to depict time to first relapse, to visual disability, to EDSS 4 and to cognitive impairment (dependent variables) among groups and groups differences were compared with log-rank test. Univariate cox proportional hazard model was performed to calculate survival rates of the aforementioned dependent variables. Independent continuous and categorical variables included sex, age at disease onset, onset clinical presentations, onset attack severity, acute therapy, second line acute therapy and time to immunosuppression. An exploratory multivariable cox proportional hazard model was performed using those predictors resulting with p-value  $< 0.10$  in the univariate model. We evaluated the possible violation of the proportional hazard assumption with Schoenfeld residuals. Statistical analysis was performed using STATA 14.0 software.

## RESULTS

### Study population

We collected data on 49 patients with paediatric-onset AQP4-IgG seropositive disease with a median disease duration of 79 months (range 2-401). Female to male ratio was 7:1 and median current age was 21 years (range 6-53). In our cohort, 38.8% (n=19) of

1  
2  
3 patients were White, 34.7% (n=17) were Black, 20.4% (n=10) were Asian and 6.1%  
4  
5 (n=3) were Mixed. Mean age at disease onset was  $12 \pm 4.1$  years.  
6

7  
8 Twelve patients were previously included in a retrospective international multicenter  
9  
10 analysis but additional 'time to' data, cognitive outcomes, acute attack treatment was  
11  
12 obtained for this analysis<sup>9</sup>.  
13

14 Table 2 shows the demographic and clinical descriptive features and groups  
15  
16 comparison. Patients with mixed Black ancestry were included in the Black ancestry  
17  
18 group as they showed similarities in demographic and clinical features.  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 2: Demographic, onset and disease course clinical features among groups in AQP4-IgG NMOSD with paediatric-onset**

	Total cohort	Sex			Age at onset			Race			
	N=49	Female N=43	Male N=6	p-value	<12 years N=19	12-18 years N=30	p-value	Black* N=20	Asian N=10	White N=19	p-value
<b>Demography:</b>											
Female n (%)	43 (87.7)	-	-	-	16 (84.2)	27 (90%)	ns	15 (75)	9 (90)	17 (89.5)	ns
F:M	7:1	-	-	-	5:1	9:1	-	7.5:1	9:1	8.5:1	-
Mean onset age years ± SD	12.0 ± 4.1	12 ± 4	11 ± 5.5	ns	-	-	-	13.5 ± 3.74	12.7 ± 3.74	9.8 ± 4.11	0.014
Median age at AQP4-IgG diagnosis years (range)	14 (3-45)	14 (3-45)	15.5 (3-31)	ns	-	-	ns	13 (3-34)	19 (9-45)	12 (3-32)	ns
Median time from onset to AQP4-IgG detection years (range)	1 (0-32)	1 (0-32)	1 (0-17)	ns	0 (0-22)	1 (0-32)	ns	0 (0-17)	7 (0-32)	0 (0-22)	0.022
Median disease duration months (range)	79 (2-401)	78 (2-401)	100 (2-219)	ns	90 (6-367)	72 (2-401)	ns	51 (5-273)	155 (2-401)	79 (2-367)	ns
Median current age years (range)	21 (7-54)	21 (7-54)	22 (15-33)	ns	19 (7-43)	24 (16-54)	ns	18 (16-43)	28 (16-54)	21 (7-43)	ns
<b>Race n (%):</b>											
Black	17 (34.7)	15 (34.9)	2 (33.3)	ns	3 (15.8)	14 (46.7)	0.025	-	-	-	-
Asian	10 (20.4)	9 (21)	1 (16.7)	ns	3 (15.8)	7 (23.3)	ns				
White	19 (38.8)	17 (39.5)	2 (33.3)	ns	12 (63.1)	7 (23.3)	0.008				
Mixed	3 (6.1)	2 (4.6)	1 (16.7)	ns	1 (5.3)	2 (6.7)	ns				
<b>Co-existent autoimmune diseases n (%)</b>	7 (14)	4 (9.3)	3 (50)	0.019	4 (21)	3 (10)	ns	3 (15)	1 (10)	3 (15.8)	ns
<b>Prodromal symptoms n (%)</b>	14 (28.6)	13 (30.2)	1 (16.7)	ns	7 (36.8)	7 (23.2)	ns	8 (40)	1 (10)	5 (26.2)	ns
<b>Onset syndromes n (%):</b>											
ON	23 (47)	19 (44.2)	4 (66.7)	ns	10 (52.6)	13 (43.3)	ns	8 (40)	6 (60)	9 (47.4)	ns
BS	24 (48.9)	23 (53.5)	1 (16.7)	ns	6 (31.6)	18 (54)	ns	10 (50)	5 (50)	9 (47.4)	ns
TM	12 (24.5)	12 (28)	0	ns	5 (26.3)	7 (23.3)	ns	6 (30)	2 (20)	4 (21)	ns
CS	14 (28.6)	12 (28)	2 (33.3)	ns	5 (26.3)	9 (30)	ns	6 (30)	2 (20)	6 (31.6)	ns
ON+TM	4 (8.2)	4 (9.3)	0	ns	1 (5.3)	3 (10)	ns	2 (10)	2 (20)	0	ns
Monofocal	36 (73.5)	31 (72)	5 (83.3)	ns	14 (73.7)	22 (73.3)	ns	15 (75)	7 (70)	14 (73.8)	ns
Multifocal	13 (26.5)	12 (28)	1 (16.7)	ns	5 (26.3)	8 (26.7)	ns	5 (25)	3 (30)	5 (26.2)	ns

1  
2

<b>Onset syndromes n (%):</b>											
ON	23 (47)	20 (46.5)	4 (66.7)	ns	10 (52.6)	14 (46.7)	ns	9 (45)	6 (60)	9 (47.4)	ns
SBS	24 (48.9)	22 (51.2)	1 (16.7)	ns	6 (31.6)	17 (56.7)	ns	9 (45)	5 (50)	9 (47.4)	ns
TM	12 (24.5)	12 (28)	0	ns	5 (26.3)	7 (23.3)	ns	6 (30)	2 (20)	4 (21)	ns
CS	14 (28.6)	11 (25.6)	2 (33.3)	ns	5 (26.3)	8 (26.7)	ns	5 (25)	2 (20)	6 (31.6)	ns
ON+TM	4 (8.2)	3 (7.0)	0	ns	1 (5.3)	2 (6.7)	ns	2 (10)	1 (10)	0	ns
Monofocal	36 (73.5)	34 (79.1)	5 (83.3)	ns	15 (79)	24 (80)	ns	15 (75)	7 (70)	14 (73.8)	ns
Multifocal	13 (26.5)	9 (21)	1 (16.7)	ns	4 (21)	6 (20)	ns	5 (25)	3 (30)	5 (26.2)	ns
<b>Severe onset attack n (%)</b>	37 (75.5)	33 (76.7)	4 (66.7)	ns	13 (68.4)	24 (80)	ns	17 (85)	8 (80)	12 (63.1)	ns
<b>Onset acute therapy n (%):</b>											
IVMP	22 (45)	20 (46.5)	2 (33.3)	ns	9 (47.4)	13 (43.3)	ns	5 (25)	7 (70)	10 (52.6)	ns
IVMP+PLEX+IVIG	10 (20.4)	9 (20.9)	1 (16.7)	ns	2 (10.5)	8 (26.7)	ns	8 (40)	1 (10)	1 (5.3)	0.018
Unknown	1 (4.1)	1 (2.3)	0	-	1 (5.3)	0	-	1 (5.3)	0	0	-
No therapy	16 (30.6)	13 (30.2)	3 (50)	ns	8 (42.1)	8 (26.7)	ns	6 (30)	2 (20)	8 (42.1)	ns
<b>Clinical course n (%):</b>											
Monophasic (MON)	8 (16.3)	7 (16.3)	1 (16.7)	ns	2 (10.5)	6 (20)	ns	5(25)	1 (10)	2 (10.5)	ns
Relapsing (R)	41 (83.7)	36 (83.7)	5 (83.3)	ns	17 (89.5)	24 (80)	ns	15 (75)	9 (90)	17 (89.5)	ns
<b>Median disease duration MON months (range)</b>	8 (2-79)	9 (2-79)	NA	-	43 (6-79)	8 (2-48)	ns	9 (6-48)	NA	41 (2-79)	-
<b>Median time to IS MON months (range)</b>	4.5 (0-20)	4.5 (0-20)	NA	-	NA	2 (0-20)	-	4.5 (1-20)	NA	NA	-
<b>Median disease duration R years (range)</b>	96 (21-401)	96 (21-401)	138 (45-219)	ns	96 (33-367)	97 (21-401)	ns	71 (21-273)	200 (38-401)	78 (21-367)	ns
<b>Median time to IS R months (range)</b>	11(0-400)	11 (0-400)	21 (2-209)	ns	10 (3-216)	19 (0-400)	ns	6 (0-209)	48 (2-400)	10 (0-216)	ns
<b>Mean annualized relapse rate (ARR)</b>	0.80 ± 0.47	0.87 ± 0.44	0.88 ± 0.7	ns	1.03 ± 0.33	0.75 ± 0.49	ns	0.80 ± 0.54	0.75 ± 0.30	0.97 ± 0.60	ns

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

1  
2

<b>First long-term immunosuppressant therapy n (%):</b>											
Azathioprine	30 (61.2)	28 (65.1)	2 (33.3)	ns	14 (73.6)	16 (53.3)	ns	9 (45)	9 (90)	12 (63.2)	ns
Mycophenolate Mofetil	7 (14.3)	5 (11.6)	2 (33.3)	ns	3 (15.8)	4 (13.3)	ns	3 (15)	1 (10)	3 (15.8)	ns
Rituximab	6 (12.2)	5 (11.6)	1 (16.7)	ns	1 (5.3)	5 (16.7)	ns	4 (20)	0	2 (10.5)	ns
Methotrexate	2 (4.1)	1 (2.3)	1 (16.7)	ns	0	2 (6.7)	-	2 (10)	0	0	-
Cyclophosphamide	2 (4.1)	2 (4.7)	0	ns	1 (5.3)	1 (3.3)	ns	1(5)	0	1 (5.3)	ns
Other <sup>a</sup>	2 (4.1)	2 (4.7)	0	ns	0	2 (6.7)	-	1 (5)	0	1 (5.3)	ns
<b>Failure of first line therapy n (%)</b>											
Azathioprine	13 (43.3)	11 (39.2)	2 (100)	ns	8 (57.1)	5 (31.2)	ns	4 (44.4)	1 (11.1)	8 (66.7)	ns
Mycophenolate Mofetil	6 (85.7)	4 (80)	2 (100)	ns	3 (100)	3 (75)	ns	2 (66.7)	1 (100)	3 (75)	ns
Rituximab	1 (16.7)	1 (20)	0	ns	0	1 (20)	ns	1 (25)	-	0	-
Methotrexate	1 (50)	1 (50)	-	-	-	1 (50)	-	1 (50)	-	-	-
Cyclophosphamide	2 (100)	2 (100)	-	-	1 (100)	1 (100)	ns	1(100)	-	1 (100)	-
<b>Median time to therapy (months)</b>	10.5 (4-46)	10 (4-38)	6.5 (4.2-9)	ns	10 (5-20)	11 (2-60)	ns	6 (2-20)	41 (18-201)	10 (5-27)	0.030
<b>Mean number of relapses before therapy</b>											
<b>±SD</b>	2.93 ± 2.28	2.9 ± 2.22	3.4 ± 1.81	ns	3.11 ± 1.45	2.82 ± 2.55	ns	2.33 ± 1.81	4.2 ± 3.29	2.83 ± 1.46	0.036
<b>ARR before starting long-term therapy</b>											
<b>±SD</b>	1.39 ± 0.75	1.31 ± 1.20	1.91 ± 2.68	ns	1.94 ± 1.81	1.18 ± 1.23	ns	0.85 ± 0.50	1.33 ± 1.39	1.94 ± 1.890	ns
<b>ARR during long-term therapy ±SD</b>	0.31 ± 0.05	0.31 ± 0.34	0.3 ± 0.41	ns	0.32 ± 0.41	0.29 ± 0.29	ns	0.35 ± 0.32	0.21 ± 0.21	0.32 ± 0.41	ns
<b>Disability after onset attack n (%):</b>											
Visual disability	6 (12.2)	5 (11.6)	1 (16.7)	ns	4 (21.1)	2 (6.7)	ns	0	1 (10)	5 (26.3)	0.033
Cognitive impairment	2 (4.1)	1 (2.3)	1 (16.7)	ns	1 (5.3)	1 (3.3)	ns	1 (5)	0	1 (5.3)	ns
EDSS 4	1 (2)	1 (2.3)	0	ns	0	1 (3.3)	ns	0	0	1(5.3)	ns
EDSS 6	2 (4.1)	2 (4.7)	0	ns	0	2 (6.7)	ns	1 (5)	0	1 (5.3)	ns
EDSS 8	1 (2)	1 (2.3)	0	ns	0	1 (3.3)	ns	1 (5)	0	0	ns
Dead	0	0	0	-	0	0	-	0	0	0	-

P-value is estimated using Fisher's exact test for proportions comparisons; t-test (sex and age at onset) and ANOVA (race) for means comparisons; Mann-Whitney U-test (sex and age at onset) and Kruskal Wallis tests (race) for medians comparisons. a) Multiple sclerosis disease modifying drugs. ON= monolateral and bilateral optic neuritis, BS= brainstem syndromes including area postrema syndrome or other brainstem syndromes; TM= transverse myelitis, CS= cerebral syndrome (including acute disseminated encephalomyelitis and diencephalic syndromes); ON+TM= neuromyelitis optica; IVMP= intravenous methylprednisolone; intravenous immunoglobulins; PLEX= plasma exchange; SD= standard deviation; EDSS= Expanded Disability Status Scale, ns=not significant. \*Patients with mixed Black ancestry were included in the Black ancestry group as they showed similarities in demographic and clinical features.

Confidential: For Review Only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46



### Demographic and onset clinical findings

White children had significant younger age at onset compared to the other races ( $p=0.008$ ) while Black children were older than other races ( $p=0.025$ ) (Table 2). Children frequently presented with area postrema and/or brainstem syndrome (BS) (48.9%;  $n=24$ ), unilateral or bilateral optic neuritis (ON) (47%;  $n=23$ , 12 had bilateral ON and 11 unilateral ON), cerebral syndromes (CS) (28.6%;  $n=14$ ), and transverse myelitis (TM) (24.5%;  $n=12$ , 9 had longitudinally extensive transverse myelitis and 3 patients had unknown spinal cord lesion length as MRI was not available at the time of their onset). Multifocal presentation, defined as two or more of the aforementioned CNS syndromes, was seen in 26.5% ( $n=13$ ) of patients. No difference in onset presentation was noted when analysing patients according to sex, age at onset or race. A severe onset attack was seen in overall 75.5% ( $n=37$ ) of patients. Onset TM events were severe (unable to walk unaided at nadir) in 9 out of 12 patients (75%) and 2 patients (16.7%) were left with EDSS 6 (unable to walk >100 m unaided) after the onset event. Onset ON events were severe (visual acuity 6/60 or worse in affected eye) in 18 out of 23 patients (78.3%) and 6 patients (26%) were left with visual disability (visual acuity in best eye worse than 6/36 on Snellen chart) after the onset event.

### Disease course

A relapsing course was observed in 83.7% ( $n=41$ ) of children with a median time to first relapse of 12 months (IQR=4-26). Overall, 52.3% patients with a minimum disease duration of one year had a relapse within one year from onset, and 66.7% of patients with a minimum disease duration of two years had a relapse within two years from onset. Median time to first relapse was 26 months (IQR=17-37) in those starting the immunosuppressive therapy around the onset attack ( $n=14$ ) while those who were not immunosuppressed at their first relapse ( $n=32$ ) had a median time to first relapse

1  
2  
3 of 5 months (IQR=3-16) ( $p=0.039$ ). It is noteworthy that those with monophasic  
4  
5 disease had a significantly shorter follow-up time compared to those with relapsing  
6  
7 disease (Table 2) but they also had a non-significant shorter time to  
8  
9 immunosuppressive treatment (median time 4.5 months versus 11 months,  $p=0.065$ ).  
10  
11 Age at onset between 12-18 years was associated with approximately half the risk of  
12  
13 relapse over time compared to those less than 12 years at onset (Figure 1 A and Table  
14  
15 3), despite no difference in time to immunosuppression between those aged <12 years  
16  
17 and those aged 12-18 years at onset was observed (Table 2). No patients had  
18  
19 progression of disability outside of relapses, and of the 8 who did not relapse none  
20  
21 developed progressive disability.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 3: Survival and univariate analysis for early predictors of time to first relapse and time to long-term disability outcomes**

	Time to first relapse (months)				Time to visual disability (months)				Time to EDSS 4 (months)				Time to cognitive impairment (months)			
	Median Survival time (IQR) <sup>a</sup>	P value (log-rank)	HR (95%CI)	P value	Median Survival time (IQR) <sup>a</sup>	P value (log-rank)	HR (95%CI)	P value	Median Survival time (IQR) <sup>a</sup>	P value (log-rank)	HR (95%CI)	P value	Median Survival time (IQR) <sup>a</sup>	P value (log-rank)	HR (95%CI)	P value
<b>Sex</b>																
Male	16 (5-17)		1 (reference)		176 (6-NR)		1 (reference)		NR (54-NR)		1 (reference)		NR (38- NR)		1 (reference)	
Female	11 (4-26)	ns	1.34 (0.47-3.87)	ns	171 (79-367)	ns	0.70 (0.19-2.48)	ns	NR (199-NR)	ns	1.05 (0.12-8.57)	ns	NR (127- NR)	ns	0.65 (0.14-2.99)	ns
<b>Age at disease onset</b>																
<12 years	5 (2-16)		1 (reference)		176 (6-367)		1 (reference)		253 (115-NR)		1 (reference)		240 (240- NR)		1 (reference)	
12-18 years	17 (9-34)	0.023	0.49 (0.25-0.93)	0.030	NR (120- NR)	0.076	0.44 (0.17-1.14)	0.093	NR (NR-NR)	ns	0.53 (0.14-1.99)	ns	NR (89- NR)	ns	1.28 (0.38-4.26)	ns
<b>Race</b>																
Black	17 (5-37)		1 (reference)		NR (171-NR)		1 (reference)		NR (199-NR)		1 (reference)		NR (150- NR)		1 (reference)	
Asian	14 (4-26)		1.45 (0.62-3.37)	ns	176 (120-NR)		1.90 (0.42-8.82)	ns	NR (NR-NR)		NA	-	NR (89- NR)		0.39 (0.07-2.22)	ns
White	6 (3-16)	ns	1.78 (0.87-3.63)	ns	79 (6-367)	0.036	4.10 (1.13-14.8)	0.032	253 (115-NR)	0.054	1.07 (0.28-4.06)	ns	240 (127- NR)	ns	0.72 (0.20-2.58)	ns
<b>Coexistent autoimmune diseases</b>																
Absent	13 (4-34)		1 (reference)		367 (86-NR)		1 (reference)		NR (199-NR)		1 (reference)		240 (127-NR)		1 (reference)	
Present	4 (2-17)	ns	2.44 (0.91-6.54)	ns	176 (38-176)	ns	1.99 (0.56-7.13)	ns	NR (8-NR)	ns	2.33 (0.46-11.8)	ns	NR (9-NR)	ns	1.29 (0.28-5.92)	ns
<b>Prodromal symptoms</b>																
Absent	11 (3-24)		1 (reference)		176 (38-NR)		1 (reference)		NR (199-NR)		1 (reference)		1 (reference)		1 (reference)	
Present	13 (5-36)	ns	0.80 (0.39-1.66)	ns	171 (171-367)	ns	0.80 (0.28-2.28)	ns	253 (115-NR)	ns	1.20 (0.30-4.81)	ns	150 (41-240)	ns	2.73 (0.87-8.50)	ns
<b>Onset symptoms ON</b>																
Absent	11 (4-26)		1 (reference)		367 (367-NR)		1 (reference)		NR (199-NR)		1 (reference)		NR (150- NR)		1 (reference)	
Present	13 (5-24)	ns	0.88 (0.47-1.64)	ns	86 (6-171)	0.0002	7.80 (2.2-27.7)	0.002	NR (NR-NR)	ns	0.69 (0.16-2.97)	ns	NR (89- NR)	ns	1.43 (0.43-4.79)	ns
<b>TM</b>																
Absent	12 (4-24)		1 (reference)		171 (79-367)		1 (reference)		253 (199- NR)		1 (reference)		240 (127- NR)		1 (reference)	
Present	7 (4-34)	ns	0.99 (0.49-2.00)	ns	NR (38-NR)	ns	0.90 (0.29-2.82)	ns	NR (8- NR)	ns	1.58 (0.39-6.43)	ns	NR (72- NR)	ns	0.98 (0.26-3.70)	ns

<b>BS</b>																
<i>Absent</i>	10 (5-29)		1 (reference)		120 (15-176)		1 (reference)		253 (253-NR)		1 (reference)		240 (89- NR)		1 (reference)	
<i>Present</i>	12 (3-26)	ns	0.90 (0.47-1.70)	ns	NR (171- NR)	0.067	0.39 (0.13-1.11)	0.078	NR (199-NR)	ns	1.25 (0.33-4.73)	ns	NR (127- NR)	ns	0.70 (0.22-2.22)	ns
<b>CS</b>																
<i>Absent</i>	9 (4-24)		1 (reference)		120 (36-NR)		1 (reference)		NR (199- NR)		1 (reference)		NR (NR - NR)		1 (reference)	
<i>Present</i>	17 (4-36)	ns	0.80 (0.39-1.65)	ns	367 (171-367)	0.072	0.34 (0.10-1.20)	0.095	253 (253- NR)	ns	1.63 (0.40-6.55)	ns	150 (72-240)	0.035	3.22 (1.02-10.2)	0.046
<b>Multifocal</b>																
<i>Absent</i>	8 (1-204)		1 (reference)		176 (79-367)		1 (reference)		NR (253- NR)		1 (reference)		NR (240- NR)		1 (reference)	
<i>Present</i>	13 (2-127)	ns	0.83 (0.37-1.81)	ns	86 (6-171)	ns	1.70 (0.63-4.63)	ns	NR (115- NR)	ns	1.35 (0.33-5.45)	ns	127 (72-150)	ns	2.07 (0.65-6.57)	ns
<b>Onset severity</b>																
<i>Mild</i>	11 (4-24)		1 (reference)		NR (NR-NR)		1 (reference)		NR (NR - NR)		1 (reference)		NR (NR- NR)		1 (reference)	
<i>Severe</i>	17 (6-37)	ns	1.86 (0.77-4.45)	ns	171 (15-367)	0.032	6.77 (0.90-51.3)	0.064	253 (199- NR)	ns	1.90 (0.24-15.2)	ns	240 (89-NR)	no	3.88 (0.50-30.3)	ns
<b>Onset AT</b>																
<i>No</i>	9 (4-36)		1 (reference)		171 (120-367)		1 (reference)		NR (253- NR)		1 (reference)		240 (89- NR)		1 (reference)	
<i>Yes</i>	13 (4-26)	ns	1.15 (0.59-2.24)	ns	171 (36-NR)	ns	2.19 (0.71-6.81)	ns	NR (199- NR)	ns	1.53 (0.35-6.70)	ns	NR (127- NR)	ns	0.91 (0.26-3.17)	ns
<b>II line AT</b>																
<i>Not required</i>	9 (4-24)		1 (reference)		176 (36-367)		1 (reference)		NA (199- NA)		1 (reference)		NR (240-NR)		1 (reference)	
<i>Required</i>	24 (13-37)	ns	0.64 (0.29-1.40)	ns	171 (86-171)	ns	0.65 (0.14-2.88)	ns	NA (NA - NA)	ns	2.20 (0.41-11.7)	ns	127 (17-127)	0.035	3.99 (1.11-14.4)	0.034
<b>Time to IS (months)</b>	-	-	0.99 (0.99-1.00)	ns	-	-	0.98 (0.97-0.99)	0.031	-	-	0.99 (0.98-1.00)	ns	-	-	0.99 (0.98-1.0)	ns

Log-rank test of Kaplan Meier curves and Univariate Cox proportional hazard model analysis of predictors of time to first relapse, to visual disability, to EDSS 4, to cognitive impairment.

a) Estimated from Kaplan Meier curves. NR= not reached; ns= not significant; EDSS= Expanded Disability Status Scale; HR= hazard ratio; IQR= interquartile range between 25° and 75° percentile; ON= optic neuritis at onset; TM= transverse myelitis at onset; BS= brainstem syndrome at onset; CS= cerebral syndrome at onset; AT= acute onset attack therapy; II line AT= plasma exchange and/or intravenous immunoglobulins; IS= immunosuppression. - = empty space when the statistical test was not applicable.

### Acute and maintenance therapy

At first clinical presentation, 65.3% (n=32) of patients were treated with intravenous methylprednisolone (IVMP) and 20.4% (n=10) required a second line acute therapy (plasma exchange [PLEX] and/or intravenous immunoglobulins [IVIG]). Children who required treatment beyond IVMP were most likely to be Black (p=0.018) and to present with multifocal involvement of CNS (p=0.004). At first clinical presentation, 30.6% (n=16) of patients did not receive acute therapy: mild sensory symptoms or an under-recognized area postrema syndrome (n=10), unilateral ON (n=5) and one patient presenting with a encephalitic illness. Excluding the initial prednisolone cover, the first non-steroid maintenance immunosuppressive therapy was initiated after a median time of 10.5 months (range 2-400). Asian children received non-steroid maintenance therapy after a significant longer median time from onset (p=0.030) and had a higher mean number of relapses (p=0.036) as compared to the White and Black groups (Table 2). In order of frequency, the most used immunosuppressants were azathioprine (AZA, 2-2.5 mg/kg/day) (61.2%), mycophenolate mofetil (MMF, 10-20 mg/kg twice daily up to a maximum of 1.5 g twice daily if adult weight) (14.3%) and rituximab (RTX, repeated 6 monthly or when CD19 count rises, <50 kg 375mg/m<sup>2</sup>, weekly for 4 doses; >50kg 1 g 2 doses two weeks apart) (12.2%) (Table 2). At last review, 16.7% (n=1) of patients had discontinued first line RTX due to neutropenia (median disease duration 55 months, range 2-140). Discontinuations with AZA and MMF were 43.3% (n=13) (median disease duration 94 months, range 2-401) and 85.7% (n=6) (median disease duration 45 months, range 21-283) respectively. The percentage of discontinuation due to relapses was 53.8% (n=7) for AZA and 66.7% (n=4) for MMF. The percentage of discontinuation due to a lack of tolerability was 46.2% (n=6) for AZA and 33.3% (n=2) for MMF. There were no differences in medication use according to sex, age at disease onset and race (Table 2). A shorter

1  
2  
3 median time to initiating immunosuppressive therapy occurred in children presenting  
4 with TM (median 4 months, range 0-400) compared to those presenting with non-TM  
5 symptoms (median 11 months, range 0-216) ( $p=0.049$ ).  
6  
7

### 8 9 **Disability outcomes**

10  
11 The onset attack left 10 patients (20.4%) with at least one residual disability: 6 with  
12 visual disability (all bilateral ON related), 4 with EDSS 4 (3 TM related and one BS  
13 related) and 2 with cognitive impairment (both CS), with 2 patients having more than  
14 one disability. In this cohort with a median disease duration of 79 months (range 2-  
15 401), 36.7% ( $n=18$ ) of patients had visual disability, 18.4% ( $n=9$ ) reached EDSS 4.0,  
16 10.2% ( $n=5$ ) reached EDSS 6 and 2% ( $n=1$ ) reached EDSS 8. Of patients presenting  
17 with ON, 26.1% ( $n=6$ ) were left with visual disability from onset. Of patients  
18 presenting with TM 25% ( $n=3$ ) were left with at least EDSS 4 due to the onset attack.  
19 Cognitive impairment was present in 24.5% ( $n=12$ ) at follow-up and all cases were  
20 related to attacks involving the brain: 2 from the onset attack and 10 during later  
21 relapses (of whom 5 had CS at onset). Five required educational support and 7 of the  
22 12 had in addition a formal neuropsychometric assessment. Although the protocols  
23 varied, the commonest findings were impairment of processing speed, executive and  
24 attention functions. Of patients presenting with cerebral syndromes attacks, 14.3%  
25 ( $n=2$ ) were left with cognitive impairment. During follow-up, two patients (4%) died.  
26 Neither died from a relapse, one died due to a choking event one year after discharge  
27 having been left with bulbar problems from onset attack and was diagnosed post-  
28 mortem. The second had cardio-respiratory arrest during the COVID-pandemic  
29 (covid-19 PCR negative) after discharge at home. By the cohort median disease  
30 duration of 79 months, 34.3% (12/35) reached visual disability, 20.7% (6/29) reached  
31 EDSS 4, 14.8% (4/27) reached EDSS 6, 4.2% (1/24) reached EDSS 8, 25.8% (8/31)  
32 reached cognitive impairment, and 4.2% (1/24) died.  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### Early predictors of long-term disability

Table 3 summarizes log-rank and univariate hazard ratios (HR) relative to early predictors of the first relapse, visual disability, EDSS 4 and cognitive impairment.

Figure 1 shows Kaplan Meier curves estimating the cumulative probability of remaining free from the aforementioned outcomes in relation to the most significant early clinical-demographical features. Multivariate cox proportional hazard model results for each outcome are provided in Table 4.

**Table 4: Multivariable Cox hazard model for early predictors of time to visual and cognitive disability**

	HR (95%CI)	P-value
<b>Time to visual disability (months)</b>		
<b>Age at disease onset</b>		
<12 years	1 (reference)	ns
12-18 years	2.43 (0.56-10.50)	
<b>Race</b>		
Black	1 (reference)	
Asian	2.14 (0.39-11.64)	ns
White	12.10 (1.91-76.61)	0.008
<b>ON at onset</b>	6.70 (1.43-31.37)	0.016
<b>BS at onset</b>	1.40 (0.37-5.84)	ns
<b>CS at onset</b>	0.14 (0.02-1.12)	0.064
<b>Severity of onset attack</b>	2.86 (0.30-27.10)	ns
<b>Time to IS</b>	0.99 (0.98-1.00)	ns
<b>Schoenfeld residuals</b>		0.850
<b>Time to cognitive impairment (months)</b>		
<b>CS at onset</b>	2.21 (0.59-8.32)	ns
<b>Second line acute therapy</b>	2.71 (0.65-11.3)	ns
<b>Schoenfeld residuals</b>		0.584

Multivariable Cox hazard model for predictors of visual disability and cognitive impairment. HR= hazard ratio; CI= confidence interval; ON= optic neuritis; BS= brainstem syndrome; CS= cerebral syndrome; IS= immunosuppression; Second line acute therapy = IVMP+ IVIG/PLEX



### *Visual disability*

ON phenotype was strongly associated with permanent visual disability (HR=7.8,  $p=0.002$ , 95%CI=2.2-27.71), even when excluded the onset attack (HR=4.34,  $p=0.041$ , 95%CI=1.06-17.8) (Figure 1B). None of the 5 patients who received second line acute therapy in addition to IVMP for onset ON (Black=3, White=1, Asian=1) developed permanent visual disability versus 46.2% (6/13) of those ON treated with IVMP only (White=5, Asian=1, Black=0).

White children were approximately four times more likely to develop permanent visual disability compared to Black children (HR=4.1,  $p=0.032$ , 95%CI=1.13-14.8) (Figure 1 C). Older children (12-18 years) at onset tended to have a non-significant longer time to visual disability than younger children (<12 years) (HR=0.44,  $p=0.093$ , 95%CI=0.17-0.15) (Table 3). Longer time to immunosuppression was associated with a lower risk of developing visual disability (HR=0.98,  $p=0.026$ , 95%CI=0.97-0.99). However, this association was lost if patients who develop visual disability from onset attack were excluded (HR=0.98,  $p=0.067$ , 95%CI=0.98-1.00), possibly due to earlier introduction of immunosuppression.

Finally, from the exploratory multivariable cox hazard model, White race and an onset which includes ON were both associated with an increased risk of visual disability (White race: HR=12.10,  $p=0.022$ , 95%CI=1.91-76.61) (ON: HR=6.70,  $p=0.016$ , 95%CI=1.43-31.34) (Table 4).

### *EDSS 4*

There was a trend toward non-Asians reaching an EDSS score of 4 considerably earlier than Asians ( $p=0.054$ ) (Figure 1D). Those with an TM onset attack did not reach EDSS 4 earlier than other primary attacks sites (Table 3).

### *Cognitive impairment*

1  
2  
3 CS presentations were associated with a greater risk of cognitive impairment than  
4 other presentations (HR=3.22, p=0.048, 95%CI=1.02-10.2) (Figure 1 E) and this  
5 association remained after exclusion of the CS onset attacks (HR=5.52, p=0.017,  
6 95%CI=1.36-22.5). Patients resistant to IVMP and treated with second line acute  
7 therapy were more likely to develop early cognitive impairment (HR=3.99, p=0.034,  
8 95%CI=1.11-14.4) (Figure 1 F). However, when these two factors were included in an  
9 exploratory multivariate hazard model the significance was lost (Table 4).  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20

## 21 DISCUSSION

### 22 Key results and interpretation

23  
24 This study reports the longest follow-up of paediatric-onset AQP4-IgG  
25 seropositive NMOSDs to date (79 months, range 2-401) and represents  
26 patients within a single country with similar environmental and treatment  
27 protocols. Some patients were diagnosed clinically at onset and confirmed  
28 when the AQP4-IgG result became available, the longest after 32 years.  
29 Children presenting under 12 years relapsed earlier than those aged 12-18 years. The  
30 non-White predominance, that has been reported in adults, was also observed in this  
31 study (2011 England and Wales census for 18-24 years old<sup>12</sup>) and predominance of  
32 Black race was greater in those aged 12-18 years as compared to those under 12 years  
33 of age. Black children were also more likely to be refractory to IVMP and require  
34 treatment with acute second line therapies. Prognostic differences were also seen:  
35 earlier time to a) motor disability in non-Asians, b) visual disability in Whites, c)  
36 cognitive impairment with IVMP resistant onset CS. Children with ON onset attacks  
37 and those with ON who did not escalate to second line acute therapies also reached  
38 visual disability earlier.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Existing studies on long-term outcomes of paediatric-onset NMOSD were limited to mixed cohorts of seropositive and seronegative patients<sup>8</sup>, had shorter disease duration<sup>7,9</sup>, or had more heterogeneity across different countries and health care systems<sup>8</sup>. However, we noted comparable demographic onset features (median age at onset, female to male ratio and Black predominance) in a single country (USA) one year of disease duration study on paediatric-onset AQP4-IgG disease<sup>7</sup>. We reported an elevated incidence of area postrema syndrome as onset presentation compared to other paediatric AQP4-IgG NMOSD studies<sup>7,9</sup>. This may relate to ‘hindsight’ diagnoses and improved awareness of the area postrema clinical presentation. RTX was superior to AZA and MMF as a first line therapy, with less discontinuations (none of the 6 patients followed for a median 4.5 years had relapses). This is in keeping with a recent multi-center study that reported no relapses in children treated with first line RTX followed for a median time of 2 years<sup>9</sup>. Despite methodological differences, similar studies found a higher probability of developing visual disability than motor disability in patients with paediatric-onset AQP4-IgG<sup>4,7,8,9</sup>. The only study investigating predictors of disability in children found a similar percentage of patients with cognitive impairment (25.4%) although with a shorter median disease duration of 4 years, and a similar relationship between long-term visual disability development and ON presentations to our study<sup>9</sup>.

The use of survival analysis adjusts for varied disease durations amongst the different subgroups categorized by age, sex, race, onset presentations and therapy and permitted to report the risk of outcome at different timelines. To our knowledge this method has not been used before to look at early predictors of disability in children and allowed us to compare our findings to a three-center study on predominantly adult-onset patients (Oxford and Liverpool, United Kingdom and Sendai, Japan)<sup>13</sup> which used the same disability outcomes definitions.

1  
2  
3 Compared to Kitley et al<sup>13</sup>, Black race predominance was greater in our paediatric-  
4 onset cohort (34.7% in children versus 20.3% in predominantly adults). We noted this  
5 was particularly marked in those with onset 12-18 years. Although racial differences  
6 in age of puberty are reported with earlier age in Black than White children, this  
7 seems unlikely to explain the rate of predominance of white children in younger ages  
8 and black children in older ages<sup>14,15,16</sup>. Unfortunately, the date of the pubertal age was  
9 not available in our cohort. The proportion of patients presenting with CS, BS and  
10 multifocal syndromes was greater in children than adults, while the proportion of  
11 those presenting with TM or with ON was respectively lower and similar in our  
12 paediatric-onset cohorts than in predominantly adult-onset cohort. Children receiving  
13 second line acute therapy due to IVMP resistance were mostly Black and with  
14 multifocal presentations. As a consequence of such severity, clinicians administered  
15 immunosuppressive therapy earlier and after lower annualized relapse rates to Black  
16 than to the other races, possibly resulting in a lower disability burden than Whites.  
17 Despite good diagnostic assays, children still had early relapses, especially in the  
18 younger age group (median time to first relapse 5 months) often before  
19 immunosuppressive therapy was started (median time 10.5 months). Time to first  
20 relapse in the older children group (17 months) was similar to the predominantly  
21 adult-onset cohort<sup>13</sup> (14 months), however that older study noted longer delay to  
22 immunosuppression than in our older children and therefore even the 12-18-year-old  
23 may have more active disease than adults.  
24  
25 The survival analysis on long-term disabilities outcomes confirmed the age effect on  
26 visual and motor disability<sup>8,13</sup>. Despite similar median disease duration, children had  
27 double the risk of visual disability compared to the predominant adults cohort (36.7%  
28 of children versus 18% of predominantly adults) but were three times less likely to  
29 reach EDSS 6 (10.2% of children versus 34% of predominantly adults) and were ten  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 times less likely to reach EDSS 8 (2% of children versus 23% of predominantly  
4  
5 adults). Four per cent of children versus 9% of predominantly adults died over the  
6  
7 similar disease durations.  
8

9  
10 We found that, as in adults and in another paediatric study<sup>9,13</sup>, ON onset predicted  
11  
12 long-term visual disability and we found interesting that its acute treatment was a  
13  
14 determinant factor. Paediatric patients with ON at onset had an higher proportion of  
15  
16 severe onset attacks at nadir and had a greater residual visual disability rate after onset  
17  
18 attack than predominantly adult-onset patients<sup>13</sup>. Our paediatric patients with TM at  
19  
20 onset had an higher proportion of severe onset attacks but, interestingly, a lower  
21  
22 proportion was left with residual motor disability compared to the adult-onset  
23  
24 cohort<sup>13</sup>. This effect may highlight a possible increased susceptibility of the optic  
25  
26 nerve and a reduced susceptibility of the spinal cord to AQP4-IgG related  
27  
28 inflammation in children compared to adults<sup>17</sup>. Moreover, while ON presentation was  
29  
30 predictive of shorter time visual disability, even excluding the onset attack influence,  
31  
32 TM presentation did not predict long-term motor disability. However, the early use of  
33  
34 immunosuppressive therapy in transverse myelitis patients over those with non-TM  
35  
36 may have contributed. Patients with ON onset refractory to IVMP who were not  
37  
38 treated with second line acute therapy were more likely to develop early visual  
39  
40 disability. Several studies have demonstrated the safety and efficacy of treating  
41  
42 refractory ON with PLEX, even in children<sup>18,19,20</sup>. Hence, we recommend the use of  
43  
44 second line acute therapy in any case that is refractory to IVMP to prevent residual  
45  
46 blindness and, although the number was too small to study the time interval, it is  
47  
48 likely the sooner acute therapy is given the better the outcome<sup>21</sup>.  
49  
50  
51  
52  
53  
54

55 We found that White race was predictive of long-term visual disability. Although in  
56  
57 the prevalent adult study<sup>13</sup> Black race was more likely to develop visual disability, in  
58  
59 our paediatric onset cohort White race had the highest risk, especially at onset attack  
60

1  
2  
3 and even adjusting for age at onset. This may reflect the inclusion of very young  
4 patients (<12 years) in our study. We found race to be predictive also of motor  
5 disability (EDSS 4), as Asian children reached EDSS 4 later than the other ethnic  
6 groups, despite having longer disease duration time, higher number of relapses and  
7 longer time to immunosuppression. This data is consistent with findings on a racial  
8 influence on motor disability<sup>13</sup>.  
9

10 We found that cognitive impairment developed in around a quarter of children and it  
11 was particularly frequent in CS presentations refractory to IVMP, even when the  
12 influence of the onset attack was removed. However, these predictors lost their  
13 significance in the multivariable Cox Hazard model analysis, possibly because these  
14 predictors were interdependent. A larger prospective study may be able to establish  
15 whether these or other predictors are present. The proportion of cognitive impairment  
16 in AQP4-IgG NMOSD adults was estimated 29-57%<sup>22</sup>, however, routine cognitive  
17 testing in AQP4-IgG seropositive patients is not consistently done and is difficult to  
18 perform in very young children, thus a direct comparison is not possible. The  
19 prolonged effect of AQP4-IgG related brain inflammation might cause irreparable  
20 damage on the cortex and its connections<sup>23</sup> possibly altering or delaying the  
21 development of the cognitive abilities in children. Cognition should be actively  
22 assessed in children and help offered from an early stage during rehabilitation and,  
23 because the risk of cognitive damage related to future attacks is greater in this group,  
24 more aggressive immunosuppression may be indicated.  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

### 50 **Limitations**

51 This study was limited by the low number of observations due to the rarity of the  
52 disease and results were not corrected for multiple comparisons. A prospective study  
53 analyzing a bigger sample of children with this disease might be useful to perform a  
54 multivariate analysis with multiple comparison correction. Noting similar  
55  
56  
57  
58  
59  
60

1  
2  
3 observations across different studies adds weight to our findings and new findings  
4  
5 require validation in future studies. Although 12 patients were included in a previous  
6  
7 report<sup>9</sup>, our study had several additional features: it was a single country study, which  
8  
9 removes heterogeneity of management regimes, with a longer disease duration  
10  
11 (median 79 months versus 48 months), time to event were used instead of outcome at  
12  
13 the end of follow-up, detailed cognitive outcomes, details of the onset attack severity  
14  
15 and its treatment were included. Due to the long follow-up, patients presenting long  
16  
17 ago might have been treated differently to those presenting currently. Future  
18  
19 paediatric predictive studies should include genetic, environmental factors (i.e.  
20  
21 passive smoking, vitamin D/sun exposure, dietary habits) serum, immunological and  
22  
23 CSF biomarkers including NFL, GFAP<sup>24,25</sup>.

## 30 CONCLUSIONS

31  
32 Paediatric-onset AQP4-IgG NMOSD is a disabling disease affecting predominantly  
33  
34 Black followed by Asian and then White children in the UK. Children have a more  
35  
36 severe onset and shorter time to first relapse than adults and show a good response to  
37  
38 first-line RTX compared to AZA and MMF. AQP4-IgG seropositive children appear  
39  
40 more susceptible to optic nerve damage and less to spinal cord damage than older  
41  
42 population studies which may reflect structural differences affecting capacity to  
43  
44 repair. Second line acute therapy may reduce visual disability in ON attacks. White  
45  
46 race and ON presentation predict future visual disability. Non-Asian ethnicities are  
47  
48 more likely to develop EDSS 4 and TM at onset is not predictive of motor disability  
49  
50 as this often occurred during subsequent TM attacks. A steroid-refractory onset attack  
51  
52 involving cerebral hemispheres predisposes to long-term cognitive impairment  
53  
54 development. With improved predictive data in paediatric AQP4-IgG NMOSD,  
55  
56 clinical trial powering can be more accurately calculated, and individualized  
57  
58  
59  
60

1  
2  
3 monitoring, support and treatment regimens can be offered with the aim of improving  
4  
5 outcomes in children.  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Confidential: For Review Only



## Acknowledgments

We would like to thank European Charcot Foundation for its support to this project.

## Contributorship

*VC, SiM, StM, ML, CH, SH, SR, JP*: conception and design of the work

*VC, SiM, KTE, JSI, RM, YH, RD, EW, MIL, SR*: acquisition and analysis of data for the work

*VC, SiM, KTE, JSI, RM, YH, RD, EW, StM, ML, CH, SH, MIL, SR, JP*: drafting the work or revising it critically for important intellectual content and agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

## Funding

European Charcot Foundation research fellowship funded Dr. Valentina Camera. No award/grant number.

## Competing of Interests

Disclosure of interests related to the present article: *VC* reports funding from European Charcot Foundation supporting for the present manuscript. No award/grant number.

Disclosure of interests unrelated to the present article: *SM* reports grants from Biogen, Novartis, Bayer, Merck, Almirall, Roche; *RD* reports grants from Barts Charity, MS Society of Great Britain, Horne Family Charitable Trust, Celgene grants and consulting fees from Merck and Biogen, consulting fees from Roche, Teva, Sanofi Genzyme, Janssen; *ML* reports consulting fees from Advisory Board Octapharma and from Advisory Board Novartis, non-financial support from Advisory Board CSL Behring, grants from NIHR, GOSH Charity, Action Medical Research; *CH* reports consulting fees from Novartis, Biogen, UCB and Roche; *JP* reports grants and consulting fees from Merck Serono, Novartis, Biogen Idec, Teva, Abide, Bayer Schering, grants from MS society, Guthie Jackson Foundation; Payment for expert testimony and support for attending meetings and/or travel from Chugai Pharma and Bayer Schering, Alexion, Genzyme, MedImmune, EuroImmune, MedDay, and ARGENX.

**Ethics approval:** The study procedure was approved by the Oxford Research Ethics Committee C Ref:10/H0606/56. All patients signed the informed consent.

**Data Sharing:** The data collected for the present study will be available from the corresponding author upon request to qualified researchers (i.e. affiliated with universities or research institutions/Hospital trusts).

1  
2  
3 Dr. Valentina Camera and Prof. Jacqueline Palace had full access to all the data in the  
4 study and take responsibility for the integrity of the data and the accuracy of the data  
5 analysis  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Confidential: For Review Only

## References

1. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. *Neurology*. 2015;85(2):177-189. doi:10.1212/WNL.0000000000001729
2. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis. *Lancet*. 2004;364(9451):2106-2112. doi:10.1016/S0140-6736(04)17551-X
3. Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. *J Exp Med*. 2005;202(4):473-477. doi:10.1084/jem.20050304
4. Absoud M, Lim MJ, Appleton R, et al. Paediatric neuromyelitis optica: Clinical, MRI of the brain and prognostic features. *J Neurol Neurosurg Psychiatry*. 2015;86(4):470-472. doi:10.1136/jnnp-2014-308550
5. Tenenbaum S, Yeh E.A., and the Gurthy-Jackson Foundation Clinical Consortium (GJCF-ICC). Pediatric NMOSD: a Review and Position Statement on Approach to Work-up and Diagnosis. *Front Pediatr*. 2020;8:339. doi:10.3389/fped.2020.00339
6. Quek AML, McKeon A, Lennon VA, et al. Effects of age and sex on aquaporin-4 autoimmunity. *Arch Neurol*. 2012;69(8):1039-1043. doi:10.1001/archneurol.2012.249
7. McKeon A, Lennon VA, Lotze T, et al. CNS aquaporin-4 autoimmunity in children. *Neurology*. 2008;71(2):93-100. doi:10.1212/01.wnl.0000314832.24682.c6
8. Collongues N, Marignier R, Zéphir H, et al. Long-term follow-up of neuromyelitis optica with a pediatric onset. *Neurology*. 2010;75(12):1084-1088. doi:10.1212/WNL.0b013e3181f39a66
9. Paolilo RB, Hacohen Y, Yazbeck E, et al. Treatment and outcome of aquaporin-4 antibody-positive NMOSD: A multinational pediatric study. *Neurol Neuroimmunol neuroinflammation*. 2020;7(5). doi:10.1212/NXI.0000000000000837
10. Waters PJ, McKeon A, Leite MI, et al. Serologic diagnosis of NMO: A multicenter comparison of aquaporin-4-IgG assays. *Neurology*. 2012; 78:665-671.
11. Casaletto KB, Heaton RK. Neuropsychological Assessment: Past and Future. *J Int Neuropsychol Soc*. 2017; 23(9-10): 778–790. doi: 10.1017/S1355617717001060
12. <https://www.ethnicity-facts-figures.service.gov.uk/uk-population-by-ethnicity/demographics/age-groups/latest#age-profile-by-ethnicity>
13. Kitley J, Leite MI, Nakashima I, et al. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. *Brain*. 2012;135(6):1834-1849. doi:10.1093/brain/aws109


- 1  
2  
3 14. Reagan PB, Salsberry PJ, Fang. MZ, Gardner WP, Pajer K. African-  
4 American/white differences in the age of menarche: accounting for the  
5 difference. *Soc Sci Med.* 2012;75(7):1263-70. doi:  
6 10.1016/j.socscimed.2012.05.018  
7
- 8  
9 15. Chumlea WC, Schubert CM, Roche AF, Kulin HE, Lee PA, Himes JH, Sun SS.  
10 Age at menarche and racial comparisons in US girls. *Pediatrics.*  
11 2003;111(1):110-3. doi: 10.1542/peds.111.1.110.  
12
- 13 16. Biro FM, Huang B, Crawford PB, Lucky AW, Striegel-Moore R, Barton BA,  
14 Daniels S. Pubertal correlates in black and white girls. *J Pediatr.*  
15 2006;148(2):234-40. doi: 10.1016/j.jpeds.2005.10.020.  
16
- 17 17. Absoud M, Greenberg BM, Lim M, et al. Pediatric transverse myelitis.  
18 *Neurology.* 2016;87(9):S46-S52. doi:10.1212/WNL.0000000000002820  
19
- 20 18. Song W, Qu Y, Huang X. Plasma exchange: an effective add-on treatment of  
21 optic neuritis in neuromyelitis optica spectrum disorders. *Int Ophthalmol.* 2019  
22 Nov;39(11):2477-2483. doi: 10.1007/s10792-019-01090-z  
23
- 24 19. Jacquet C., Garnier A and Cheuret E. Plasma Exchange and Immunoabsorption  
25 in Pediatric Inflammatory Optic Neuropathy Resistant to Corticosteroid  
26 Therapy: Four French Cases. *Neuropediatrics.* 2016;47(3):175-8. doi:  
27 10.1055/s-0036-1578797.  
28
- 29 20. Merle H, Olindo S, Jeannin S, et al. Treatment of optic neuritis by plasma  
30 exchange (add-on) in neuromyelitis optica. *Arch Ophthalmol.* 2012;130(7):858-  
31 62. doi: 10.1001/archophthalmol.2012.1126.  
32
- 33 21. Kleiter I, Gahlen A, Borisow N, et al. Neuromyelitis Optica: Evaluation of 871  
34 attack and 1,153 Treatment Courses. *Ann Neurology.* 2016;79:206-2016. doi:  
35 10.1002/ana.24554.  
36
- 37 22. Czarnecka D, Oset M, Karlińska I, et al. Cognitive impairment in NMOSD-  
38 More questions than answers. *Brain Behav.* 2020;10(11):e01842. doi:  
39 10.1002/brb3.1842.  
40
- 41 23. Saji E, Arakawa M, Yanagawa K, et al. Cognitive Impairment and Cortical  
42 Degeneration in Neuromyelitis Optica. *Ann Neurol.* 2013 (1);73:65–76. doi:  
43 10.1002/ana.23721.  
44
- 45 24. Aktas O, Smith MA, Rees WA et al. Serum Glial Fibrillary Acidic Protein: A  
46 Neuromyelitis Optica Spectrum Disorder Biomarker. *Ann Neurol.*  
47 2021;89(5):895-910. doi: 10.1002/ana.26067.  
48
- 49 25. Watanabe M., Nakamura Y, Michalak Z, et al. Serum GFAP and neurofilament  
50 light as biomarkers of disease activity and disability in NMOSD. *Neurology.*  
51 2019. 24;93(13):e1299-e1311. doi: 10.1212/WNL.00000000000008160.  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 **Figure 1: Most significant Kaplan Meier curves illustrating early predictors affecting**  
4 **the probability of remaining free from first relapse, visual disability, EDSS 4, and**  
5 **cognitive impairment**  
6  
7

- 8  
9 A. Time to first relapse was significantly shorter in children aged < 12 years at onset than those  
10 aged 12-18 years.  
11 B. Time to permanent visual disability was shorter in those who had optic neuritis (ON) at onset  
12 than those who did not.  
13 C. Time to permanent visual disability was shorter in the White than Black and Asian, and this  
14 difference was mainly due to the onset attack outcomes.  
15 D. Time to EDSS 4 was significantly longer in Asian than Black and White.  
16 E. Time to cognitive impairment was significantly shorter in those who presented a cerebral  
17 syndrome at onset (CS) than those who did not.  
18 F. Time to cognitive impairment was significantly shorter in those who were treated with second-  
19 line acute therapy (IVIG or PLEX) than those who did not receive second-line acute therapy  
20 (no therapy or IVMP).  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Supplementary Table 1:**

<b>Neuropsychological tests list</b>
Assessment of Comprehension and Expression (ACE)
Babcock story recall test
The Brain Injury Rehabilitation Trust Memory and Information Processing Battery (BMIPB)
Boston naming test
Brixton spatial anticipation test
Category fluency
California Verbal Learning Test Children's (CVLT-C)
CVTL-C-II-long delay
Delayed recall test
Digit span test
Divergent naming
Hayling Sentence Completion test
Logical Memory tests
Measure of Cognitive Linguistic Abilities (MCLA)
Procedural narrative
Phonemic verbal fluency
Symbol-Digit Modalities Test (SDMT)
Unconnected completion test
Wechsler Adult Intelligence Scale -IV (WAIS-IV)
Wechsler Memory Scale -IV (WMS-IV)
Wide Range Achievement Test 4 (WRAT-IV)



210x310mm (200 x 200 DPI)